No connection

Search Results

LPCN vs ZJYL

LPCN
Lipocine Inc.
BEARISH
Price
$2.38
Market Cap
$17.4M
Sector
Healthcare
AI Confidence
95%
ZJYL
Jin Medical International Ltd.
BEARISH
Price
$2.15
Market Cap
$16.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
LPCN
--
ZJYL
10.78
Forward P/E
LPCN
-1.92
ZJYL
--
P/B Ratio
LPCN
1.01
ZJYL
0.57
P/S Ratio
LPCN
8.79
ZJYL
0.82
EV/EBITDA
LPCN
-0.29
ZJYL
7.14

Profitability

Gross Margin
LPCN
100.0%
ZJYL
30.18%
Operating Margin
LPCN
-219.65%
ZJYL
9.83%
Profit Margin
LPCN
0.0%
ZJYL
5.76%
ROE
LPCN
-54.28%
ZJYL
4.75%
ROA
LPCN
-32.81%
ZJYL
0.77%

Growth

Revenue Growth
LPCN
-67.2%
ZJYL
-16.5%
Earnings Growth
LPCN
--
ZJYL
-32.0%

Financial Health

Debt/Equity
LPCN
0.03
ZJYL
0.64
Current Ratio
LPCN
6.68
ZJYL
1.85
Quick Ratio
LPCN
6.36
ZJYL
1.53

Dividends

Dividend Yield
LPCN
--
ZJYL
--
Payout Ratio
LPCN
0.0%
ZJYL
0.0%

AI Verdict

LPCN BEARISH

LPCN exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.68 and negligible debt, these are offset by a catastrophic 67.2% year-over-year revenue collapse and an operating margin of -219.65%. The technical trend is entirely bearish (0/100), and the stock has lost over 90% of its value over five years. Despite a lone analyst's optimistic $11.00 target, the data suggests a company in operational distress.

Strengths
Very low debt-to-equity ratio (0.03)
Strong short-term liquidity (Current Ratio 6.68)
Trading near book value (P/B 1.01)
Risks
Severe revenue decline (-67.2% YoY)
Critical financial health score (Piotroski 0/9)
Extreme negative operating margins (-219.65%)
ZJYL BEARISH

ZJYL presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 6/9 and a price significantly below its Graham Number ($4.13), yet plagued by severe fundamental decay. While the company maintains a healthy balance sheet with a current ratio of 1.85 and low debt/equity (0.64), it is suffering from catastrophic growth contraction, with revenue down 16.5% and earnings down 32% YoY. The massive 87.7% decline in share price over the last year reflects a market that has completely lost confidence in the company's growth trajectory. Despite trading at a deep discount to book value (P/B 0.57), the lack of positive catalysts and bearish technical trend outweigh the valuation appeal.

Strengths
Trading significantly below book value (P/B 0.57)
Stable financial health indicated by Piotroski F-Score of 6/9
Strong liquidity position with a Current Ratio of 1.85
Risks
Severe revenue contraction (-16.5% YoY)
Sharp decline in earnings growth (-32% YoY)
Catastrophic 1-year price performance (-87.7%)

Compare Another Pair

LPCN vs ZJYL: Head-to-Head Comparison

This page compares Lipocine Inc. (LPCN) and Jin Medical International Ltd. (ZJYL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile